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Abstract
Background. Diagnostic testing in cystic fibrosis (CF) is based on the sweat chloride test 
(SCT) in the context of appropriate signs and symptoms of disease and results of the gene 
mutation analysis. In 2014 the Istituto Superiore di Sanità (ISS) established a pilot Italian 
external quality assessment program for CF sweat chloride test (Italian EQA-SCT). In 
2015 this activity was recognized as a third party service carried out by the ISS. The aim 
of the paper is to compare 2015 and 2016 results and experiences.
Methods. The scheme is prospective; enrollment is voluntary and the payment of a fee is 
required. Participants are registered and identified by a specific Identification Number 
(ID) through a dedicated web-facility. Assessment covers analysis, interpretation and 
reporting of results.
Results. Thirteen and fifteen laboratories, participated in the 2015 and 2016 round 
respectively. Seven laboratories participated constantly from 2014, eleven participated 
both in 2015 and 2016 and four participated in 2016 for the first time. Variability in 
scores of chloride titration and heterogeneity in interpretation/reporting results were 
detected in both rounds. A total of 18 critical errors in chloride titration were made by 
eight different participants. Four laboratories made errors in chloride titration in 2015 
but drastically improved their performance in 2016. In 2016 poor performance criteria 
were established and adopted.
Conclusions. Even though results show variability in performance of laboratories, con-
stant and mandatory participation may contribute to the improvement of performance 
and quality reached by laboratory. 
INTRODUCTION
Cystic fibrosis (CF, OMIM 219700) is a life-limiting 
autosomal recessive disorder that affects ~70 000 indi-
viduals worldwide. The condition affects primarily those 
of European descent, although cystic fibrosis has been 
reported in all ethnicities. Twenty-eight years ago, a 
mutation in the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) gene was found to be the most 
common cause of CF. Identification of disease-causing 
variants in CFTR contributed a tool for both the di-
agnosis of cystic fibrosis and the identification of CF 
carriers, demonstrated the degree to which CFTR dys-
function correlates with clinical features. The identifica-
tion of more than 2000 CFTR mutations/variants, ei-
ther CF causing or with variable clinical consequences, 
and genotype-phenotype studies revealed that CFTR 
dysfunction due to several variants can create different 
phenotypes in the cystic fibrosis disease spectrum. Over 
the past few years, there has been remarkable progress 
in the development of small-molecule therapy targeting 
CFTR bearing select disease-causing variants as correc-
tors and/or potentiators of the protein [1]. 
Diagnostic testing in CF is based on the sweat chlo-
ride test (SCT) in the context of appropriate signs and 
symptoms of disease and results of the CFTR gene mu-
tation analysis. The SCT is a well-established functional 
assessment of CFTR that has been available for decades 
to diagnose CF [2] and, recently, to test the effect of 
CFTR modifier therapies [3]. A general significant cor-
relation between the SCT and clinical manifestations 
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has been recently described; however, the same geno-
type can give rise to a wide range of sweat test values 
and highly similar sweat test values may be observed in 
populations with different clinical manifestations [4].
Italian recommendations for appropriate execution 
and interpretation of sweat test suggest how to correct-
ly perform analyses and interpret results [5].
The precise number of Italian laboratories perform-
ing sweat test nationwide is actually not known since 
there is not any updated census available; however we 
know for sure that 37 laboratories, belonging to the Ital-
ian Referral Care Centres for Cystic Fibrosis, perform 
SCT.
It is of critical importance that SCT is carried out ac-
curately with measurement of relevant analytes to allow 
clinical interpretation of results. Two Italian audits per-
formed in 2006 and repeated in 2009 showed areas of 
inconsistencies in current practices for SCT, highlight-
ing the needs of national initiatives aimed to improve 
the general performance of sweat test [6, 7]. In order 
to increase and monitor quality in laboratories perform-
ing SCT, an Italian EQA-SCT pilot program was per-
formed in 2014 at the Italian National Centre for Rare 
Diseases (CNMR) of the Istituto Superiore di Sanità 
(ISS, Rome); in 2015 the activity was recognized as in-
stitutional and therefore permanent as reported in the 
Official Bulletin of the Italian Republic [8-10]. In 2016 
poor performance criteria were introduced. Aim of this 
study is to compare results of the 2015 and 2016 EQA-
SCT rounds.
MATERIALS AND METHODS
The pilot Italian EQA-SCT has been fully described 
by Salvatore et al. [9, 10]. The program is performed 
once per year. Overall thirteen and fifteen laboratories, 
among the 37 Italian CF public Referral Care Centers, 
participated in 2015 and 2016 respectively. It is not 
possible to state the total number of Italian laboratories 
performing SCT and the percentage participating to the 
Italian EQA-SCT program since there is no updated 
and available census at the moment. Participation is 
voluntary. An Identification Number (ID) was assigned 
to each laboratory by the scheme organizer (ISS). In 
the present paper laboratories are identified by a pro-
gressive alphabetical ID from a to q.
Seven laboratories participated constantly to Italian 
EQA-SCT from 2014 (pilot experience [9, 10], namely 
laboratories a, c, e, f, g, h, i); eleven participated to both 
rounds (a, c, e, f, g, h, i, j, k, l, m) and four participated 
in 2016 for the first time (laboratories n, o, p, q). Labo-
ratories b and d participated in 2015 round but not in 
the 2016 one.
Assessment
A panel of experts, composed by representatives from 
both ISS and National Scientific Societies involved in 
cystic fibrosis research, clinics and management (Ital-
ian Cystic Fibrosis Society, SIFC; Italian Society for 
the Study of Inborn Metabolic Diseases and Newborn 
Screening, SIMMESN;, Italian Society of Clinical Bio-
chemistry and Clinical Molecular Biology, SIBiOC), 
assessed all the results, both online (by using a dedi-
cated web-facility) and collegially in de visu meetings or-
ganized by the ISS. All data were treated anonymously 
and the identity of each laboratory was unknown to the 
assessors.
Assessment covered analytical performance, interpre-
tation and reporting of results according to the Italian 
guidelines [5]. Table 1 summarizes assessment criteria 
and scores assigned for each parameter in 2015 and 
2016. 
The qualitative description of the laboratories was as-
sessed in the pilot and in the 2015 round through re-
ports and an ad hoc online pre-test questionnaire ad-
ministered to all participants [9].
In 2015 and in 2016 two main categories were taken 
into account and are discussed in the present paper: a) 
technical adequacy in performing sweat chloride test that in-
cludes stimulation method, sweat collection, analytical 
method; b) quantitative analytical performance per sam-
ple, i.e. reporting information, chloride concentration 
value, clinical sensitivity (Table 1). 
Reporting information assessment consisted in the 
evaluation of the correctness and completeness of the 
following criteria: patient identification data; date of 
test; date of sample collection; date of report; weight 
and volume of sweat collected; indication of insufficient 
collection (< 75mg); stimulation method; analyte(s); 
analytical method; chloride reference intervals (normal 
results if < 40 mEq/L; < 30 mEq/L in subjects less than 
6 months of age; intermediate results if 40-60 mEq/L, 
30-60 mEq/L insubjects less than 6 months of age, ab-
normal if > 60 mEq/L); interpretation of results; pres-
ence of report signature; report clear legibility.
Clinical sensitivity was defined as the consistency of 
a sweat chloride result with the correct range and the 
clinical interpretation of the result. 
In 2016 Italian EQA-SCT poor performance crite-
ria were also established and poor performance was 
assigned to laboratories when i) exceeding more than 
50% the reference values in chloride concentration ti-
tration, or ii) getting titration value(s) wrong because of 
unintentional sample exchange and/or clerical or tran-
scription errors, or iii) submitting a report where the 
results interpretation was missing or wrong and/or iv) 
submitting reports where fundamental information was 
missing.
Samples
Three sweat-like-samples (SLS) were commercially 
prepared (LTA s.r.l., Milano, Italy) and consisted of 
an aqueous material mining the normal sweat compo-
sition; in particular they contained: dipotassium car-
bonate, lactic acid, carbamide, glucose, albumin, thi-
merosal, demineralised water and NaCl (this latter at 
established range concentrations). 
Two independent ISS Working Units quantified and 
validated all samples before dispatch performing a 
minimum of 40 measures/sample; the reference value 
was defined as the mean of all measures. The samples 
dispatch of 0.5 mL per aliquot, labeled with specific 
identification codes (namely “Sample I-EQA-SLS-1”, 
“Sample I-EQA-SLS-2” and “Sample I-EQA-SLS-3”; 
Table 2), was single and performed once per year at 
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room temperature; mock clinical information togeth-
er with technical data was provided (Table 2) [9, 10]. 
Laboratories had to analyze samples according to their 
routine procedures.
Data management and results elaboration
All data were managed through a dedicated web-fa-
cility [9, 10] and, in order to compare 2015 and 2016 
data, results concerning “technical adequacy in per-
forming sweat chloride test” were normalized (total 
maximum score = 10) and those ones relative to “quali-
tative description of the structure” were not taken into 
account as mentioned above in the “assessment” sec-
tion (Table 2 and Table 3).
RESULTS
Thirteen laboratories participated in the 2015 Italian 
EQA-SCT and 15 in 2016. Eleven participated to both 
rounds; two laboratories participated only in 2015 (lab-
oratory b and d) and 4 only in 2016 (laboratory n to p).
A great variability between 2015 and 2016 was ob-
served for chloride concentration and clinical sensitiv-
ity. Scores, related to the assessment of all parameters, 
ranged from 30.6/100 to 94.7/100 in 2015 (median 
score = 70.5/100) (Figure 1 and Table 1) and 20/100 to 
100/100 in 2016 (median score = 81.3/100) (Figure 1 
and Table 2).
Score per parameter is described in Figure 1; “techni-
cal adequacy in performing sweat chloride test” results 
were satisfactory in both rounds.
A significant variability in evaluation of chloride ti-
tration was instead observed both in 2015 and in 2016 
(Figure 1; Table 1 and 2); a total of 18 critical errors 
in chloride titration (12 errors in 2015 and 6 errors in 
2016; score range = 0 to 0.9) were made by eight dif-
ferent participating laboratories (namely a, f, g, i, j, k, 
m, p). Laboratories f, g and k participated to both 2015 
and 2016 schemes. Laboratories a, j, i, and m made er-
rors in chloride titration samples in 2015 but drastically 
improved their performance in 2016 and their score 
changed from 8.3/30 to 20.4/30 for laboratory a, 8,1/30 
to 19,7/30 for laboratory i; 16/30 to 30/30 for labora-
Table 1
Assessment criteria and scores assigned
Technical adequacy in performing sweat chloride test (2015 and 2016)
Stimulation method*
10 (2015)
3.3 (2016)
if by pilocarpine nitrate 
0 (2015)
0 (2016)
other methods
Sweat collection *
10 (2015)
3.3 (2016)
if onto filter paper
0 (2015)
0 (2016)
other methods
Analytical method *
10 (2015)
3.3 (2016)
if by coulometry, colorimetry, ISEs
0 (2015)
0 (2016)
other methods
Quantitative analytical performance (2015 and 2016)
Reporting information*
(patient identification data; date of test; date of sample 
collection; date of report; weight and volume of sweat 
collected; indication of insufficient collection (< 75mg); 
stimulation method; analyte(s); analytical method; 
chloride reference intervals (normal results if < 40 
mEq/L; < 30 mEq/L in subjects less than 6 months of 
age; intermediate results if 40-60 mEq/L, 30-60 mEq/L 
insubjects less than 6 months of age; abnormal if > 60 
mEq/L); interpretation of results; presence of report 
signature; report clear legibility)
10 (per sample)
if complete and correct
0 to 9 (per sample)
if not complete and or not correct
Chloride concentration value
0 to 10 (per sample)
Values exceeding the 75% (50% in 2016) of the reference values were not included 
in the analyses (i.e. for an expected 20 mEq/L Cl– concentration value, all values 
reported as more than 35 mEq/L were not included in the following calculation). 
A 20% of error was accepted for an expected value of 20 mEq/L; 10% of error 
was accepted for an expected value of 100 mEq/L. A proportional % of error was 
considered for all the values between 20 and 100 mEq/L. 
Clinical sensitivity 10 (per sample)correct
0 (per sample)
not correct
Qualitative description of the structures (assessed only in 2015 round)
Number of test/year * 10 
(> than 200 tests per year) 
0 
(< than 200 tests per year) 
Number of test/year/technician* 10
(> than 50 tests per year)
0
(< than 50 test per year)
Time of test execution * 10 
(≤ 24 hrs)
8 
(> 24 hrs and < than 48 hrs)
0 
(72 hrs or more)
*Assessment based on the Italian Sweat Test Guidelines [5]
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tory j and 9.7/30 to 21.3/30 for laboratory m (Figure 1). 
Laboratory p was a first time participating laboratory 
and wrong chloride titration of all the three samples in 
2016. 
Technical adequacy in performing sweat chloride test
Technical adequacy in performing sweat chloride test 
included stimulation method, sweat collection and ana-
lytical method assessment. Both in 2015 and 2016 al-
most all laboratories reach the highest score (10/10). In 
2015 laboratories a and d obtained a “0” score in “ana-
lytical method” and “stimulation method” assessment 
respectively since these information were not reported 
in their reports (Table 3 and Table 4).
Quantitative analytical performance
SLS-1
2015: Reference value 20.25 mEq/L; Mean value: 19.76 
mEq/L; interpretation: “unlikely CF”
2016: Reference value 35.66 mEq/L; Mean value: 35.10 
mEq/L; interpretation: “intermediate result which requires 
further cystic fibrosis assessment”
In 2015 chloride concentration results ranked from 
0/10 to 9.8/10 (mean score = 3.7/10); five laboratories 
(f, i, j, k and m) got a wrong chloride titration and were 
marked with 0 to 0.7 score (Table 3).
In 2016 chloride concentration results ranked from 
0/10 to 10/10 (mean score = 7.9); laboratories f (partici-
pating also to 2015 round) and p (participating in 2016 
for the first time) were marked with a 0 score (Table 4). 
Clinical sensitivity results in 2015 were good for al-
most all laboratories except for laboratory k (score 0/0); 
error was due to a not appropriate use of adopted refer-
ence intervals. 
In 2016 three laboratories reported a wrong interpre-
tation of results: laboratory k was marked with a 0 score 
since interpretation of results was not present in the re-
port sent to providers. Also laboratories p and q (first 
time participating) didn’t include an interpretation of 
results in their reports and were both marked with 0 
score. 
Of note, clinical sensitivity of sample SLS-1 is not 
comparable between 2015 and 2016; in 2015 interpre-
tation was referred to an “unlikely CF” and in 2016 to 
an “intermediate result which requires further cystic fibrosis 
assessment”; this may be reflected on the better results 
obtained in the first round (2015).
SLS-2
2015: Reference value 39.53 mEq/L; Mean value: 4176 
mEq/L; interpretation: “intermediate result which requires 
further cystic fibrosis assessment” 
2016: Reference value 5496 mEq/L; Mean value: 5680 
mEq/L; interpretation: “intermediate result which requires 
further cystic fibrosis assessment”
Chloride concentration results ranked from 0/10 to 
9.3/10 (mean score = 4.2/10). Six laboratories (namely 
a, e, f, i, k, m) out of 13 (46.15%) made a wrong mea-
surement in chloride titration (ranking score from 0/10 
to 0.7/10). 
Table 2
Samples mock clinical and technical information provided to participating laboratories in 2015 and 2016 I-EQA-SCT program. 
Mean Cl− value is the median of all the measurements from laboratories
Sample Mock 
clinical information
Sweat collected 
(information 
provided by EQA 
provider)
(mg)
Reference 
value
(mEq/L)
Chloride 
concentration 
mean value
(mEq/L)
Expected correct 
interpretation
I-EQA-SLS-1 2015 Three years old child with recurrent 
bronchial pneumonia and chronic 
cough.
102 20.25 19.76 “unlikely CF”
2016 Thirty days aged female identified as 
part of a screening programme with 
raised IRT and carrier of a CF-causing 
mutation.
86 35.66 35.10 “intermediate result 
which requires 
further cystic fibrosis 
assessment”
I-EQA-SLS-2 2015 Two months old asymptomatic 
female positive to CF neonatal 
screening.
80 39.53 41.76 “intermediate result 
which requires 
further cystic fibrosis 
assessment”
2016 Sixty-two aged male, grandfather of 
a female child with two CF-causing 
mutations. The patient has chronic 
bronchopneumopathy and cirrhosis.
120 54.96 56.80 “intermediate result 
which requires 
further cystic fibrosis 
assessment”
I-EQA-SLS-3 2015 Sixteen years old boy with 
inadequate weight gain and 
recurrent respiratory infections.
130 200.00 195.95 “non-physiological 
value: results should 
be questioned”
2016 Child with infection-induced 
wheezing, negative neonatal 
screening, two acute pancreatitis 
episodes and pancreas divisum 
diagnosis.
92 100.00 115.45 “supports a 
diagnosis of cystic 
fibrosis”
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In 2016 almost all laboratories except laboratory p 
(score = 0, first time participating) obtained good re-
sults and rank was from 6.2/10 to 10/10.
As regards clinical sensitivity, two laboratories (k and 
m) obtained a critical score in interpretation in 2015. 
A poor score was assigned to laboratory k due to a not 
appropriate use of adopted reference intervals while 
laboratory m completely missed the interpretation of 
results. In 2016, three laboratories (laboratories k, p, q) 
missed interpretation of results and were marked with 
a “0” score. Laboratories p and q participated for the 
first time. 
SLS-3 
2015: Reference value 200.00 mEq/L; Mean value: 195.95 
mEq/L; interpretation: “non-physiological value: results 
should be questioned” 
2016: Reference value 100.00 mEq/L; Mean value: 115.45 
mEq/L; interpretation: “supports a diagnosis of cystic fibrosis”
In 2015 chloride concentration results ranked from 
0.9/10 to 9.7/10 (mean score = 6.0/10). Only laboratory 
f made a wrong chloride titration (0.9/10). 
In 2016 chloride concentration results ranked from 
0/10 to 10/10 (mean score = 5.1/10); three laboratories 
obtained a critical score (namely laboratories g, k and p).
Table 3
Italian EQA-SCT 2015 general results
PARTICIPANTS IN 2015 Italian EQA-SCT ROUND
a b c d e f g h i j k l m min 
score
mean 
score
max 
score
Technical adequacy in performing sweat chloride test  
Stimulation method 3.3 3.3 3.3 0.0 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 0.0 3.0 3.3
Sweat collection 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
Analytical method 0.0 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 0.0 3.0 3.3
min score 0.0 3.3 3.3 0.0 3.3 3.3 3.3 3.3 0.0 0.0 3.3 3.3 3.3
mean score 2.2 3.3 3.3 2.2 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3  
max score 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
Quantitative analytical performance
• Sample SLS-1. Reference Cl- value: 20.25 mEq/L; expected interpretation: “unlikely CF”
Reporting information 9.5 10.0 9.5 3.5 9.5 10.0 10.0 10.0 10.0 10.0 7.5      8.5 8.0 3.5 8.9 10
Chloride concentration 
value
5.7 8.1 9.8 8.1 4.4 0.0 5.7 2.5 0.7 0.0 0.0 3.2 0.0 0 3.7 9.8
Clinical sensitivity 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 0.0 10.0 10.0 0 9.2 10
min score 5.7 8.1 9.5 3.5 4.4 0 5.7 2.5 0.7 0 0 3.2 0
mean score 8.4 9.4 9.8 7.2 8.0 6.7 8.6 7.5 6.9 6.7 2.5 7.2 6.0
max score 10 10 10 10 10 10 10 10 10 10 7.5 10 10
• Sample SLS-2.  Reference Cl- value: 39.53 mEq/L; expected interpretation: “intermediate result which requires further cystic fibrosis assessment”
Reporting information 8.0 10.0 9.5 3.5 10.0 10.0 10.0 10.0 10.0 10.0 6.0 8.5 8.0 3.5 8.7 10
Chloride concentration 
value
0.7 9.3 6.9 7.9 9.2 0.0 0.0 3.7 0.0 9.2 0.0 7.9 0.0 0 4.2 9.3
Clinical sensitivity 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 0.0 10.0 0.0 0 8.5 10
min score 0.7 9.3 6.9 3.5 9.2 0 0 3.7 0 9.2 0 7.9 0
mean score 6.2 9.8 8.8 7.1 9.7 6.7 6.7 7.9 6.7 9.7 2.0 8.8 2.7
max score 10 10 10 10 10 10 10 10 10 10 6 10 8
• Sample SLS-3.  Reference Cl- value: 200 mEq/L; expected interpretation: “non-physiological value: results should be questioned”
Reporting information 9.5 10.0 9.5 3.5 10.0 10.0 10.0 10.0 10.0 10.0 6.0 8.5 7.0 3.5 8.8 10
Chloride concentration 
value
1.9 7.4 3.7 8.0 5.8 8.0 0.9 8.2 7.4 6.8 1.2 9.1 9.7 0.9 6.0 9.7
Clinical sensitivity 10.0 10.0 0.0 0.0 0.0 10.0 0.0 0.0 10.0 0.0 0.0 0.0 0.0 0 3.1 10
min score 1.9 7.4 0 0 0 8 0 0 7.4 0 0 0 0
mean score 7.1 9.1 4.4 3.8 5.3 9.3 3.6 6.1 9.1 5.6 2.4 5.9 5.6
max score 10 10 9.5 8 10 10 10 10 10 10 6 9.1 9.7
TOTAL MAX SCORE 
FOR ALL CATEGORIES 
= 100
71.9 94.7 78.8 61.1 78.8 77.9 66.5 74.3 78 75.9 30.6 75.6 52.6 30.6 70.5 94.7
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As regards clinical sensitivity, in 2015, nine labora-
tories out of 13 (69.23%) obtained a critical score in 
clinical sensitivity as they didn’t report that the chloride 
value was not physiological and consequently the result 
should have been questioned. In 2016, three laborato-
ries (k, p, q) obtained a 0 score due to the lack of inter-
pretation of results.
Reports assessment
Both in 2015 and 2016 almost all reports were in-
complete, missing information concerning one or more 
parameters. Total scores ranged from 0/30 to 30/30 
(median score = 20.8) in 2015 and 10.5/30 to 30/30 
(median score = 26.1) in 2016 (Figure 1). In 2015 most 
frequently missing information concerned “interpre-
tation of results” (15.4% in sample SLS-1; 30.8% in 
sample SLS-2 and 15.4% in sample SLS-3), “reference 
intervals” (23.0%, in SLS-1 and SLS-2, 30.8% in SLS-3), 
and “weight and volume of sweat collected” (15.4% in 
SLS-1 and SLS-2, 23% in SLS-3).
In 2016 lacking information was referred to “date of 
primary sample collection” (33.3%, in SLS-1, SLS-2 
and SLS-3), “analytical method” (20% in SLS-1, SLS-2 
and SLS-3) and “interpretation of results” (20% in all 
samples).
Poor performance
Three laboratories were marked as poor performers 
(k, p and q). Laboratory k participated to both 2015 
and 2016 EQA-SCT rounds: poor performance was 
assigned due to lack of interpretation of results in all 
samples (SLS-1, SLS-2 and SLS-3). Furthermore, this 
laboratory obtained a 0 score in chloride concentration 
titration for sample SLS-3. Its final score was 54/100.
Laboratories p and q participated for the first time in 
2016: laboratory p was marked as poor performer due 
to both an insufficient score in chloride concentration 
titration (score = 0 in SLS-1, SLS-2 and SLS-3) and to 
the lack of interpretation of results for all the samples; 
its final score was 20/100.
Laboratories q also was marked as a poor performer 
due to lack of interpretation of results and its final score 
was 49/100.
DISCUSSION
Diagnostic testing in CF is based on the SCT in the 
context of appropriate signs and symptoms of disease 
and results of the gene mutation analysis; so far in fun-
damental to monitor patients during studies or treat-
ments with CFTR correctors/potentiators/amplifiers, 
where accurate results are required. Recent papers 
identify different issues about laboratories standardiza-
tion in execution, interpretation and reporting of results 
[6, 7, 11-13].
The first Italian national program on external quality 
assessment for CF SCT was piloted in 2014; in 2015 
this activity was recognized as a third party service car-
ried out by the ISS [8] and thereafter the first official 
round started and was completed.
Ten laboratories participated in the 2014 pilot round; 
thirteen laboratories were enrolled in 2015 and sixteen 
in 2016. Seven laboratories participate constantly since 
2014 and eleven since 2015. It is not possible to state 
the exact percentage of laboratories performing SCT 
and participating in the Italian EQA-SCT, since there is 
no updated census available; a dedicated working group 
of the Italian Cystic Fibrosis Society is currently work-
ing on it. Therefore, we can only say that about 30% of 
Italian laboratories, belonging to the public cystic fibro-
sis Referral Care Centers, are currently monitored for 
Figure 1
I-EQA-SCT2015/2016 score per parameter.
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CF SCT. In order to increase the number of volunteers 
participants in the 2017 round, the program was pro-
moted through ISS and scientific societies websites as 
well as discussed results in dedicated CF meeting ses-
sions at national level.
Quantitative analytical performance in both 2015 and 
2016 was characterized by a significant heterogeneity. 
In particular, there was a variability in scores as re-
gards the evaluation of chloride titration both in 2015 
and in 2016; 16 errors in Cl– titration (score = 0) were 
made by eight different participating laboratories. Three 
laboratories (f, g and k) participated to both 2015 and 
Table 4
Italian EQA-SCT 2016 general results
PARTICIPANTS IN 2016 Italian EQA-SCT ROUND
a c e f g h i j k l m n o p q min 
score
mean 
score
max 
score
Technical adequacy in performing sweat chloride test  
Stimulation 
method
3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
Sweat collection 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
Analytical method 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
min score 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
mean score 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
max score 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
Quantitative analytical performance
Sample SLS-1.  Reference Cl- value: 35.66 mEq/L; expected interpretation: “intermediate result which requires further cystic fibrosis assessment”
Reporting 
information
10.0 9.5 10.0 10.0 9.0 9.0 10.0 9.0 8.0 10.0 10.0 10.0 7.5 2.5 5.0 2.5 8.6 10.0
Chloride 
concentration 
value
8.3 10.0 6.2 0.0 10.0 10.0 6.7 10.0 10.0 10.0 10.0 10.0 10.0 0.0 7.6 0.0 7.9 10.0
Clinical sensitivity 10.0 10.0 10.0 5.0 10.0 10.0 10.0 10.0 0.0 10.0 10.0 10.0 10.0 0.0 0.0 0.0 7.7 10.0
min score 8.3 9.5 6.2 5.0 9.0 9.0 6.7 9.0 0.0 10.0 10.0 10.0 7.5 0.0 0.0
mean score 9.4 9.8 8.7 5.0 9.7 9.7 8.9 9.7 6.0 10.0 10.0 10.0 9.2 0.8 4.2
max score 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 8.0 10.0 10.0 10.0 10.0 2.5 7.6
Sample SLS-2.  Reference Cl- value: 54.96 mEq/L; expected interpretation: “intermediate result which requires further cystic fibrosis assessment”
Reporting 
information
10.0 9.5 10.0 10.0 9.0 9.0 10.0 9.0 8.0 10.0 10.0 10.0 7.5 4.0 5.0 4.0 8.7 10.0
Chloride 
concentration 
value
9.1 10.0 10.0 10.0 10.0 6.2 10.0 10.0 10.0 10.0 10.0 10.0 10.0 0.0 10.0 0.0 9.0 10.0
Clinical sensitivity 10.0 10.0 10.0 10.0 10.0 5.0 10.0 10.0 0.0 10.0 10.0 10.0 10.0 0.0 0.0 0.0 7.7 10.0
min score 9.1 9.5 10.0 9.0 9.0 5.0 10.0 9.0 0.0 10.0 10.0 10.0 7.5 0.0 0.0
mean score 9.7 9.8 10.0 10.0 9.7 6.7 10.0 9.7 6.0 10.0 10.0 10.0 9.2 1.3 5.0
max score 10.0 10.0 10.0 10.0 10.0 9.2 10.0 10.0 10.0 10.0 10.0 10.0 10.0 4.0 10.0
Sample SLS-3.  Reference Cl- value: 100.00 mEq/L; expected interpretation: “supports a diagnosis of cystic fibrosis”
Reporting 
information
10.0 9.5 10.0 10.0 9.0 9.0 10.0 9.0 8.0 10.0 10.0 10.0 7.5 4.0 5.0 4.0 8.7 10.0
Chloride 
concentration 
value
3.0 10.0 6.6 10.0 0.3 1.0 3.0 10.0 0.0 8.4 1.3 10.0 6.2 0.0 6.2 0.0 5.1 10.0
Clinical sensitivity 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 0.0 10.0 10.0 10.0 10.0 0.0 0.0 0.0 8.0 10.0
min score 3.0 9.5 6.6 10.0 0.3 1.0 3.0 9.0 0.0 8.4 1.3 10.0 6.2 0.0 0.0
mean score 7.7 9.8 8.9 10.0 6.4 6.7 7.7 9.7 2.7 9.5 7.1 10.0 7.9 1.3 3.7
max score 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 8.0 10.0 10.0 10.0 10.0 4.0 6.2
TOTAL MAX 
SCORE FOR ALL 
CATEGORIES = 
100
90.0 98.0 93.0 85.0 87.0 79.0 90.0 97.0 54.0 98.0 91.0 100.0 89.0 20.0 49.0 20.0 81.3 100.0
Laboratories in bold participated to both 2015 and 2016 I EQA-SCT round. Laboratories highlighted in grey (k. p and q) were assessed with a “poor performance” score 
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2016 schemes. In this respect, it is generally a good idea 
for laboratories to have well-written standard operat-
ing procedures that are based on published guidelines; 
these should, along with training, address the issues of 
execution, interpretation and reporting of results.
Four laboratories (a, j, i, and m ) made a wrong chlo-
ride titration in 2015, but drastically improved their 
performance in 2016 by 45% on average. Laboratory 
p made an error and participated for the first time in 
2016. 
Currently we cannot exclude that errors are due to 
methodological, equipment or technical problems 
caused by the unskilled personnel [14] but data re-
ferred to the four laboratories that improved their per-
formance encourage a long-lasting participation.
In 2016 poor performance criteria were established 
and adopted and three laboratories (k, p and q) received 
such a categorization.
Poor-performing laboratories were encouraged to 
review their internal processes and to contact a dedi-
cated working group within the Italian Cystic Fibrosis 
Society. Single occurrences of poor performance should 
be logged as an incident and used as an opportunity to 
review procedures and make improvements. A careful 
evaluation of the error may determine whether there 
is a system failure that may require re-design of a test, 
more frequent instrument calibration, or adjustments to 
training procedures. However, EQA may detect serial or 
persistent failures that the laboratory is obligated to ad-
dress with a more fundamental review [15] and it will be 
interesting to monitor eventual failure in future rounds.
As regards clinical sensitivity, in 2015 about 70% of 
laboratories failed to make suggestions when the chlo-
ride value was reported as not physiological (sample 
SLS-3) as clearly indicated by National Guidelines 
[5]. In 2016 three laboratories (k, p and q) obtained 
a 0 score in clinical sensitivity assessment due to the 
complete lack of interpretation of results in all samples 
sent by the provider. Noteworthy, in two out of three 
cases (laboratory k and q) analytical results were correct 
(Table 4). 
Heterogeneity was observed in the modality of results 
reporting. Most frequently missing information con-
cerned “reference intervals”, “date of primary sample 
collection” and in particular “interpretation” that af-
fected clinical sensitivity as previously discussed. 
Variability in results also indicates that EQA partici-
pation should become mandatory as a component of 
laboratory accreditation, the quality of laboratory per-
formance is unpredictable [16].
All data collected highlight the need and the impor-
tance to continue this activity constantly in order to 
support laboratories performing sweat chloride test and 
to ensure adequate quality standards. 
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